000265292 001__ 265292
000265292 005__ 20190619220216.0
000265292 022__ $$a2047-4830
000265292 022__ $$a2047-4849
000265292 02470 $$a000463226900003$$2isi
000265292 0247_ $$a10.1039/c8bm01470a$$2doi
000265292 037__ $$aARTICLE
000265292 245__ $$aSurgery-free injectable macroscale biomaterials for local cancer immunotherapy
000265292 260__ $$c2019$$aCambridge$$bROYAL SOC CHEMISTRY
000265292 269__ $$a2019-03-01
000265292 336__ $$aReviews
000265292 520__ $$aImmunotherapy can harness the power of host's immune system to fight cancer. In the last few decades, tremendous progress has been made in this field, with remarkable clinical successes achieved consisting of a durable response in a fraction of patients. However, there are enormous challenges to extending this therapy to the majority of cancer patients while retaining minimal adverse effects. Local immunotherapy is a promising approach for concentrating immunomodulation in situ without systemic exposure, therefore minimizing systemic toxicities. More importantly, local immunomodulation can still lead to systemic effects that confer overall anticancer immunity to eradicate disseminated diseases. To facilitate these local immunotherapies, a wide range of biomaterials have been developed as delivery systems to protect the locally injected immune-related therapeutics and extend their retention. Surgery-free injectable macroscale biomaterials are one of the most promising classes of biomaterials developed to date, as they are suitable for minimally invasive injection with needles or catheters and form a biocompatible three-dimensional matrix in situ as a drug-depot for controlled local delivery. In this mini-review, we provide an overview of the recent advancements in applying injectable macroscale biomaterials in local cancer immunotherapy by highlighting some recent examples. We compare various injectable biomaterials with different gelation mechanisms and discuss their applications in the delivery of immunomodulators, immune cells, and cancer vaccines. We also discuss current challenges and provide a perspective for the future development of injectable macroscale biomaterials in cancer immunotherapy.
000265292 650__ $$aMaterials Science, Biomaterials
000265292 650__ $$aMaterials Science
000265292 6531_ $$aimmunostimulatory dna hydrogel
000265292 6531_ $$at-cell therapy
000265292 6531_ $$asupramolecular hydrogels
000265292 6531_ $$adendritic cells
000265292 6531_ $$athermosensitive hydrogels
000265292 6531_ $$abiodegradable hydrogels
000265292 6531_ $$asustained-release
000265292 6531_ $$adrug-delivery
000265292 6531_ $$ain-vivo
000265292 6531_ $$acpg dna
000265292 700__ $$g279797$$0251090$$aLei, Kewen
000265292 700__ $$aTang, Li$$0250159$$g270859
000265292 773__ $$k3$$j7$$q733-749$$tBiomaterials Science
000265292 909CO $$ooai:infoscience.epfl.ch:265292$$preview
000265292 961__ $$afantin.reichler@epfl.ch
000265292 973__ $$aEPFL$$sPUBLISHED$$rREVIEWED
000265292 980__ $$aREVIEW
000265292 980__ $$aWoS
000265292 981__ $$aoverwrite
000265292 999C0 $$pLBI$$zMarselli, Béatrice$$mli.tang@epfl.ch$$0252583$$xU13294